Can Taurine and NAC Help Chronic Kidney Disease? Dr. Fowad’s Evidence Review

Kidney Health Evidence Review · Pakistan

Taurine and N-acetylcysteine have plausible antioxidant and cell-protective biology. A small 2026 randomized combination trial reported a hypothesis-generating albuminuria result in a 24-person subgroup. It did not show that either ingredient slows CKD, prevents dialysis or should be used routinely.

Medically reviewed by Dr. Fowad Shahzad · Evidence current through 20 August 2026 · Next review 31 March 2027

Patients with chronic kidney disease often ask a reasonable question: if oxidative stress contributes to kidney injury, could antioxidants such as taurine or N-acetylcysteine (NAC) protect the kidneys?

The honest answer is more interesting than either “yes” or “no.” Laboratory studies and animal models provide a credible biological rationale. Several small human studies have produced signals in albuminuria, cystatin C, inflammation or cardiovascular markers. A recent small multicentre trial, DELAY-CKD, published in March 2026, tested taurine and NAC together in adults with early-to-moderate CKD.

But the same trial also shows why these agents have not become routine treatment worldwide. Most overall comparisons—including eGFR, creatinine and urine ACR—did not establish a statistically clear treatment effect. The standout urine-ACR result arose in a subgroup of only 24 participants. The study was short, used a fixed combination, lost 20% of randomized participants from its efficacy analysis, excluded many common CKD populations and was funded by the product manufacturer.

That makes taurine plus NAC a promising research question, not a proven kidney therapy.

Dr. Fowad’s evidence-based interpretation: “Taurine and NAC deserve serious study, particularly in early albuminuric CKD. The present evidence supports a signal, not a new standard of care. Clinical authority is not the ability to make a supplement sound powerful; it is the discipline to distinguish plausible biology, an early human signal and proven outcome benefit.”

The 60-second answer

• Taurine has biologically plausible kidney effects. It participates in cell-volume regulation, membrane and calcium balance, and inflammatory or oxidative pathways. Most supportive kidney evidence, however, remains laboratory or animal research.
• NAC is a real medicine, not merely a wellness supplement. It replenishes cysteine used to make glutathione and has established medical uses for paracetamol poisoning and as a mucolytic in some formulations. Those uses do not prove that it slows CKD.
• The 2026 DELAY-CKD trial is hypothesis-generating, not practice-changing. It tested taurine and NAC together for six months. Conventional between-group analyses for eGFR, creatinine, cystatin C and overall urine ACR were not statistically significant; a secondary bootstrap analysis of cystatin C was positive but remains hypothesis-generating. One very small albuminuria subgroup had a nominally positive result.
• Neither agent has been shown to prevent dialysis, kidney transplantation, heart attack or death in a definitive CKD trial. Biomarker movement is not the same as a patient-important outcome.
• NAC does not reliably protect the kidneys from iodinated contrast. Two large trials were neutral, and current guidance does not recommend it for that purpose.
• Advanced CKD changes the safety equation. Kidney failure markedly alters NAC exposure. In a tiny high-dose haemodialysis study, taurine accumulated dramatically and caused reversible dizziness or vertigo despite dialysis.
• Neither taurine nor NAC should replace proven care. Cause-specific diagnosis, blood-pressure and diabetes management, ACE inhibitor or ARB therapy when indicated, SGLT2 inhibitors for eligible patients, selected finerenone use, cardiovascular-risk reduction and avoidance of nephrotoxins have much stronger outcome evidence.

Safety first: CKD changes how medicines and supplements are handled. Do not start taurine, NAC, a combination product or an energy drink for CKD without review of your eGFR, medicines and exact product label. Seek urgent medical care for new severe breathlessness, chest pain, fainting, confusion, facial or tongue swelling, wheeze, persistent vomiting, rapidly worsening swelling or markedly reduced urine.

First understand what would count as a real CKD benefit

CKD trials can measure several different things. They are not interchangeable.

What common CKD research measures can—and cannot—prove

Measure	What it can tell us	What it cannot prove by itself
Urine ACR (albumin-to-creatinine ratio)	How much albumin is leaking into urine; persistent reduction can be encouraging	That kidney scarring has reversed, dialysis will be prevented or a person will live longer
Serum creatinine and creatinine-based eGFR	An estimate of kidney filtration when interpreted in context and over time	Structural kidney repair; creatinine can be influenced by muscle, diet, hydration, medicines and laboratory methods
Cystatin C	An alternative filtration marker that can help when creatinine is difficult to interpret	A hard clinical benefit on its own
Oxidative-stress or inflammatory markers	Whether a biological pathway changed	Fewer cases of kidney failure, cardiovascular disease or death
Sustained eGFR decline, kidney failure, dialysis, transplantation, hospitalization, cardiovascular events or death	Patient-important outcomes used to establish disease modification	These require larger and longer trials than short biomarker studies

Albuminuria is clinically important, and a reproducible reduction can support kidney protection when it comes from a sufficiently large, well-designed trial. But a single subgroup result over six months cannot carry the same evidentiary weight as a large outcome trial.

Dr. Fowad’s evidence-based interpretation: “A lower urine ACR can be encouraging, but I would not call CKD reversed until a therapy shows durable kidney-function and patient-important benefit in adequately powered trials.”

What is taurine?

Taurine is an amino-sulfonic acid found naturally in the body and in foods, particularly animal-source foods. Unlike amino acids used to build proteins, taurine has several other physiological roles. It contributes to bile-acid conjugation, cellular osmoregulation, membrane stability, calcium handling and signalling in the nervous system, heart, muscle and other tissues.

The kidney is central to taurine balance. Healthy kidneys can conserve taurine when intake is low and excrete excess when intake is high. Renal cells also use taurine as an osmolyte—a molecule that helps cells manage changes in water and solute concentration.

Why researchers think taurine might matter in CKD

CKD is associated with inflammation, altered mitochondrial function and oxidative stress. In cell and animal models, taurine can modify some of these pathways. Selected models of diabetic kidney injury, glomerular disease and high-glucose exposure have shown less lipid oxidation, inflammation, protein leakage or tissue injury.

This is a valid reason to perform human trials. It is not proof that a taurine capsule reaches the right tissue concentration, produces net clinical benefit or remains safe as kidney clearance falls. Some experimental kidney-injury models have not shown benefit.

Food taurine, supplement taurine and energy drinks are not equivalent

Taurine consumed as part of ordinary food comes with a much smaller and more gradual exposure than a concentrated supplement. Energy drinks are multi-ingredient products that may also contain caffeine, sugar, sodium, stimulants or other compounds relevant to blood pressure, glucose, sleep and heart rhythm. They are not CKD treatment and should not be used as a taurine-delivery strategy.

“Natural” describes origin; it does not establish the safe supplemental dose in reduced kidney function.

For broader evidence-led food and supplement reviews, visit Smart Diet & Nutrition.

What is N-acetylcysteine (NAC)?

NAC, also called acetylcysteine, is a derivative of the amino acid cysteine. It can supply cysteine for glutathione synthesis and can participate in thiol-redox reactions. Glutathione is an important intracellular defence system, which makes NAC attractive for diseases involving oxidative stress.

NAC has well-established uses that must be separated from CKD supplementation:

• it is an antidote used urgently after potentially toxic paracetamol exposure; and
• some oral or inhaled formulations are used to reduce the viscosity of thick respiratory secretions.

Those uses are supported for specific indications, routes and regimens. They do not establish a chronic CKD indication. A patient with suspected paracetamol poisoning should never delay emergency care because an article questions NAC as a kidney supplement.

Why NAC might appear to “improve creatinine” without repairing the kidney

NAC can interfere with some creatinine measurements, particularly at high intravenous concentrations. A systematic review of six studies involving 199 participants found a small fall in measured creatinine but no corresponding change in cystatin C. The effect was much larger with high-dose intravenous NAC, supporting laboratory interference rather than improved filtration.

This matters because creatinine-derived eGFR automatically inherits any measurement problem. A tiny creatinine fall after NAC is not, by itself, proof of kidney healing.

Dr. Fowad’s evidence-based interpretation: “A plausible antioxidant pathway is a reason to run a trial, not a substitute for one. I would not label a small creatinine fall as kidney recovery without corroborating evidence.”

The evidence ladder: how strong is the case?

Evidence strength for taurine and NAC in CKD

Evidence level	What exists	Responsible conclusion
Cell and animal work	Multiple mechanistic studies for taurine and NAC; results differ by kidney-injury model	Supports biological plausibility, not human treatment efficacy
Small human biomarker studies	Changes in ACR, cystatin C, homocysteine, inflammation, endothelial function or residual urine in selected populations	Useful for designing larger trials; not proof of less kidney failure or death
Systematic reviews	Mixed, heterogeneous antioxidant and NAC studies; few trials contribute to each kidney endpoint	Suggests uncertainty and possible signals, but cannot establish either agent as routine therapy
2026 randomized combination trial	Six-month taurine-plus-NAC trial with favourable directions and one small A2-albuminuria subgroup result	Important new signal requiring independent replication
Large hard-outcome CKD trial	None for taurine, NAC or their combination as chronic CKD therapy	The main missing piece
Major guideline adoption	Neither agent appears in KDIGO’s disease-modifying CKD treatment framework	Not routine standard care

A close look at the 2026 DELAY-CKD trial

DELAY-CKD is the most relevant new evidence. It was a six-centre, double-blind, randomized, placebo-controlled study conducted in India. One hundred adults aged 18–65 with CKD stages 1–3 were assigned to a fixed taurine-plus-NAC product or matching placebo for 180 days, alongside standard care and advice for a low-protein diet.

The study’s low-protein advice is not a do-it-yourself treatment protocol. Protein needs differ by CKD stage, dialysis status, age and nutritional risk. Unnecessary restriction can contribute to protein-energy wasting; dietary changes should be individualized with the treating team or a renal dietitian.

The efficacy analysis included 80 participants who completed the protocol—42 in the combination group and 38 in the placebo group.

What the overall results showed

Overall biomarker results in the 2026 DELAY-CKD trial

Outcome over 180 days	Taurine + NAC	Placebo	Between-group result
Mean urine ACR change	−18.57%	+7.03%	p=0.321
Mean cystatin-C change	−21.46%	+17.71%	p=0.079
Mean serum-creatinine change	+0.03 mg/dL	+0.19 mg/dL	p=0.229
Mean eGFR change	−0.52 mL/min/1.73 m²	−1.44 mL/min/1.73 m²	p=0.785

The directions look favourable for several biomarkers, but the conventional overall comparisons did not establish a statistically clear treatment effect.

A later nonparametric bootstrap analysis of cystatin-C change was statistically significant overall (empirical p=0.004) and in several subgroups. Because this secondary sensitivity analysis used the same small per-protocol sample and multiple subgroup comparisons, it is supportive but not confirmatory and does not establish slower CKD progression.

The small subgroup signal

Among participants with A2, or moderately increased, albuminuria—historically called microalbuminuria—urine ACR fell by 34.09% in the combination arm and rose by 180.18% in the placebo arm. The nominal p value was 0.043.

That is the most encouraging result, but only 10 combination participants and 14 placebo participants were in this subgroup. With several outcomes and multiple small stage- and albuminuria-based subgroup analyses, a chance-positive result becomes more likely. The result must be replicated in a larger, prespecified A2-albuminuria trial.

What the trial did not establish

The trial did not show that taurine plus NAC:

• prevents sustained eGFR decline;
• reduces kidney failure, dialysis or transplantation;
• prevents cardiovascular events or death;
• works in CKD stage 4 or 5, dialysis or kidney transplantation;
• is safe in pregnancy, childhood, adults older than 65 or people with BMI above 30;
• works because of taurine, because of NAC or because of a particular interaction between them;
• or is equivalent across retail formulations.

No participant in either group reached dialysis, transplantation or treatment-escalation endpoints during six months. That reflects a short, clinically stable study—not proof that the combination prevented those events.

Why funding and analysis matter

Twenty of the 100 randomized participants did not enter the per-protocol efficacy analysis. Per-protocol analysis can answer what happened among completers, but it gives up some of randomization’s protection when people are excluded after allocation. The advised low-protein diet was not formally verified.

The manufacturer of the tested product funded the trial, and one author was a company employee. Industry funding does not make a result false. It does make independent replication and transparent intention-to-treat analysis especially important.

The trial reported mild adverse events in five participants in the combination arm and none in the placebo arm. All affected participants recovered without sequelae; swelling and tingling were judged likely or probably related to treatment. With only 100 randomized participants and six months of follow-up, the study cannot exclude uncommon or longer-term harms.

Dr. Fowad’s evidence-based interpretation: “The 2026 randomized trial deserves attention, not overstatement. It found an encouraging ACR signal in a very small subgroup. Conventional overall eGFR, creatinine, cystatin-C and ACR comparisons were not statistically significant; a secondary cystatin-C bootstrap analysis was positive but remains hypothesis-generating. Because taurine and NAC were used together, we cannot honestly tell patients which ingredient helped, whether both were necessary, or whether the result will be reproduced.”

What did earlier taurine-plus-NAC studies show?

Earlier human studies were small and inconsistent.

• A three-month report in 41 people with type 2 diabetes and albuminuria found a fall in urine ACR within the 31-person combination group, but the comparison group had only 10 people, randomization was not clearly described and GFR did not significantly improve.
• A 2019 study reported non-significant changes in albuminuria and TGF-β, without significant creatinine or eGFR improvement.
• A 24-week 2017 study of 60 people with diabetic nephropathy found no significant difference in proteinuria progression among NAC, NAC-plus-taurine and placebo groups.
• A 2022 three-arm, open-label study in 69 people with non-diabetic CKD did not produce its favourable conclusion from the taurine combination; the reported positive statistical finding concerned NAC plus pyridoxamine.

These studies help explain the continued interest. They also show why one new subgroup signal cannot erase an inconsistent evidence base.

What does the broader antioxidant literature show?

A 2023 Cochrane review included 95 studies, 10,468 randomized participants and 49 different antioxidant interventions. Across this highly mixed group, antioxidants did not reduce all-cause mortality. The pooled effect on urine ACR was essentially neutral and very uncertain. Some pooled kidney-failure and cardiovascular signals were favourable, while pooled infection and heart-failure risks were higher.

These are not taurine-specific results and should not be presented as such. Only one NAC-plus-taurine study was included, and it was not pooled because its outcomes were reported narratively. The review’s central lesson is that grouping dozens of different antioxidants, populations and regimens creates heterogeneity and cannot prove that a particular supplement works.

NAC alone in chronic CKD and dialysis

Non-dialysis CKD

Direct small randomized studies have often been neutral. A 20-person crossover study found no reduction in proteinuria or tubular-injury/fibrosis markers when NAC was added to ACE inhibitor or ARB therapy. A double-blind 60-person stage-3 CKD study found no short-term effect on creatinine, cystatin C, urine protein or creatinine clearance.

A 2021 meta-analysis of 15 trials and 768 participants reported modest improvements in creatinine/eGFR and fewer cardiovascular events. Its foundation was fragile: only three trials contributed eGFR data, the creatinine difference was only about 0.04 mg/dL, no trial reported all-cause mortality, and the cardiovascular result was driven largely by one small haemodialysis study. Interpretation was limited by heterogeneous populations, routes, doses and durations, incomplete outcome data, few contributing trials for several endpoints, and risk-of-bias concerns.

Haemodialysis

One 2003 trial in 134 haemodialysis patients reported fewer events in a broad cardiovascular composite with NAC, but no significant reduction in cardiovascular mortality, total mortality or the individual secondary outcomes. A small later open-label study suggested better preservation of residual filtration over three months, but it was not a hard-outcome trial.

NAC pharmacokinetics also change in kidney failure. In one ESRD study, oral clearance was about 90% lower than in healthy controls, total exposure was roughly seven times higher and the half-life was about 13 times longer. Haemodialysis can remove some NAC. These observations make do-it-yourself extrapolation from a healthy person or respiratory-product label unsafe.

NAC and iodinated contrast: an important myth

NAC became popular as a “kidney shield” before angiography or contrast imaging after small early studies reported less creatinine-defined acute kidney injury. Large rigorous trials did not confirm that result.

• In ACT, 2,308 at-risk angiography patients had exactly the same rate of contrast-associated AKI with NAC and placebo: 12.7% versus 12.7%.
• In PRESERVE, 4,993 analysed high-risk patients had no reduction in the 90-day composite of death, dialysis or persistent kidney impairment (4.6% versus 4.5%) and no reduction in contrast-associated AKI (9.1% versus 8.7%).

KDIGO 2024 states that NAC has not shown consistent benefit for preventing contrast-associated AKI. Canadian radiology guidance and other current consensus documents do not recommend routine NAC prophylaxis.

This failure does not prove that NAC can never influence a chronic CKD pathway. It proves why antioxidant plausibility and small creatinine studies are insufficient grounds for adoption.

Dr. Fowad’s evidence-based interpretation: “NAC’s contrast-protection story is a lesson in evidence humility: early positive studies did not survive large rigorous testing. That is why a new small CKD signal should be followed carefully rather than converted into a promise.”

Taurine in advanced CKD and dialysis: the major safety warning

Studies of taurine levels in dialysis patients do not produce a simple deficiency story. Some find low plasma or muscle taurine, while others find higher predialysis plasma levels and different patterns across platelets and blood cells. Dialysis can lower circulating levels, but plasma concentration, intracellular stores and clinical need are not interchangeable. There is no validated taurine-deficiency threshold that identifies CKD patients who benefit from supplementation.

The most direct safety warning comes from a 2002 taurine-accumulation report. Investigators planned to enrol 10 haemodialysis patients in an open high-dose taurine study but stopped after the first four:

• two participants developed dizziness or non-rotatory vertigo;
• symptoms resolved within 24 hours of stopping;
• symptoms returned in one patient when taurine was restarted at half the prior exposure;
• in two people with paired measurements, plasma taurine rose by 5,513% and 1,780%, and muscle taurine rose by 239% and 351%; and
• dialysis did not adequately prevent accumulation.

This was a tiny, old, high-dose study. It does not prove that every lower exposure is unsafe. It does prove that “taurine is natural, therefore harmless in kidney failure” is an unsafe claim.

Dr. Fowad’s evidence-based interpretation: “The kidney is part of taurine’s safety system. As kidney function falls, the same exposure can behave differently. Dialysis did not prevent major accumulation in a small high-dose study, so stage 4–5 CKD and dialysis are not places for unsupervised experiments.”

Why are taurine and NAC not widely used worldwide for CKD?

The answer is not suppression, professional ignorance or the low price of an “overlooked cure.” It is an evidence-and-safety gap.

1. The trials are too small and short. The newest randomized study analysed only 80 completers over six months.
2. There is no taurine-only CKD efficacy trial of sufficient quality. Combination studies cannot identify which component, if either, produced a signal.
3. Most endpoints are biomarkers. ACR, creatinine, cystatin C, homocysteine and oxidative markers are not the same as sustained eGFR preservation, fewer cardiovascular events, avoided dialysis or longer life.
4. The main 2026 conventional overall comparisons were non-significant. The clearest positive finding came from a 24-person subgroup and requires replication.
5. Common CKD populations were not studied. Advanced CKD, dialysis, transplant recipients, pregnancy, adults older than 65, type 1 diabetes and BMI above 30 kg/m² were excluded from DELAY-CKD.
6. Dose, formulation and product quality are unresolved. A trial of one fixed pharmaceutical product cannot validate every supplement or effervescent formulation sold online or in pharmacies.
7. Reduced kidney function changes exposure and safety. Taurine depends on renal excretion, and ESRD markedly changes NAC pharmacokinetics.
8. Major guidelines demand reproducible outcome evidence. KDIGO’s disease-modifying framework is built on large trials showing kidney or cardiovascular benefit; taurine and NAC have not reached that threshold.
9. There is opportunity cost. An unproven supplement can add pill burden, expense, sodium or interactions while distracting from blood pressure, glucose, ACR monitoring and proven treatment.
10. The recent trial with the most discussed signal needs independent replication. Manufacturer funding does not invalidate it, but it heightens the need for an independent trial with prespecified outcomes and intention-to-treat analysis.

Dr. Fowad’s evidence-based interpretation: “The reason these agents are not routine worldwide is not that nephrologists have ignored them. The trials remain too small, too short and too dependent on surrogate biomarkers, while dose and safety in advanced CKD remain unresolved. If the signal is real, the next step is a better trial—not louder marketing.”

What kidney-protective care has stronger evidence?

No supplement discussion should displace the treatments that already reduce kidney and cardiovascular risk in appropriately selected patients.

Current CKD care may include:

• identifying the cause and confirming chronicity rather than treating a creatinine number alone;
• tracking both eGFR and urine ACR;
• controlling blood pressure with an individualized target;
• an ACE inhibitor or ARB for indicated albuminuric CKD, with kidney function and potassium monitoring;
• an SGLT2 inhibitor for eligible patients with CKD, including many people without diabetes;
• a nonsteroidal mineralocorticoid receptor antagonist with proven kidney or cardiovascular benefit—currently finerenone in the outcome-trial framework—for selected adults with type 2 diabetes, persistent albuminuria despite maximum tolerated RAS blockade, eGFR above 25 mL/min/1.73 m² and normal potassium, with potassium and kidney-function monitoring;
• individualized diabetes, lipid and cardiovascular-risk treatment;
• stopping or limiting NSAIDs and reviewing all prescriptions, OTC medicines, herbal products and supplements;
• smoking cessation, vaccination, physical activity, sodium and dietary planning suited to the person’s CKD stage, potassium, phosphate, nutritional state and comorbidities; and
• timely nephrology or cause-specific referral when risk, diagnosis or progression warrants it.

KDIGO 2024 specifically advises reviewing and limiting OTC medicines and dietary or herbal remedies that may harm people with CKD. It recommends ACE inhibitor/ARB therapy in defined albuminuria groups and SGLT2 inhibitors for several high-risk CKD populations. These recommendations are backed by outcome evidence—not by the popularity of a product.

For persistent albumin in urine, see the guide to protein in urine assessment. People with diabetic kidney risk should also prioritize comprehensive diabetes care rather than focusing on a single supplement.

Safety: who should not self-start taurine or NAC?

No person with CKD should start a concentrated taurine, NAC or combination product solely from an article. Individual review is especially important for:

• CKD stage 4 or 5, dialysis or rapidly changing kidney function;
• kidney transplantation or immunosuppressive therapy;
• pregnancy, breastfeeding, childhood or age above 65;
• uncontrolled blood pressure, recurrent dizziness, dehydration, heart failure or fluid restriction;
• asthma or a history of bronchospasm;
• peptic-ulcer disease or significant gastrointestinal symptoms;
• a bleeding disorder, planned surgery, anticoagulant/antiplatelet treatment or extensive polypharmacy—human interaction evidence is limited, so this is a medication-review precaution rather than proof of a harmful interaction;
• planned contrast, surgery or an acute illness;
• products that are effervescent, multi-ingredient, imported, decanted or do not clearly state their full formulation and regulatory details; and
• energy-drink use.

Taurine-specific concerns

• Reduced renal excretion can permit accumulation as kidney function falls.
• Because taurine lowered blood pressure in some non-CKD trials, additive dizziness or hypotension is a theoretical concern with antihypertensives or dialysis ultrafiltration.
• There is no validated CKD dose adjustment, blood target, monitoring schedule or stop rule.
• Food-safety or supplement-enlistment status is not approval to treat CKD.

NAC-specific concerns

• Oral NAC can cause unpleasant taste or odour, nausea, abdominal discomfort, vomiting, diarrhoea, indigestion, mouth irritation or headache.
• Intravenous NAC is a different medical exposure and can cause flushing, rash, hypotension, wheeze, bronchospasm or serious hypersensitivity. It belongs in supervised care.
• Effervescent products may contain clinically relevant sodium; exact labels matter in CKD, oedema or hypertension.
• High-dose intravenous NAC can alter creatinine measurement.
• Kidney failure markedly changes NAC exposure, and dialysis can remove some of the drug.

In Pakistan, DRAP regulates medicines and also alternative medicines/health products, but registration or enlistment of a product is not automatically a CKD treatment indication. This article makes no claim that a particular taurine/NAC product is DRAP-authorized, available, effective or supplied by Dr. Fowad’s clinics. The exact product, manufacturer, formulation and approved use would require live, product-specific verification.

Populations not established as safe or effective

Pregnancy or breastfeeding, children, kidney-transplant recipients and adults older than 65 were not represented in DELAY-CKD, so no CKD-specific efficacy, dose or safety conclusion can be inferred for them. Transplant recipients should review every supplement with their transplant team because interaction data are incomplete, immunosuppressant exposure requires careful control and unreviewed ingredients can complicate graft monitoring. Pregnancy, breastfeeding and paediatric use require review by the relevant specialist and pharmacist.

Myths versus facts

Myth 1: “Taurine and NAC detoxify the kidneys.”

Fact: “Detox” is not a measurable CKD outcome. NAC has defined biochemical and antidote roles; neither agent has been shown to cleanse or regenerate chronically scarred kidneys.

Myth 2: “The 2026 trial proved the combination slows CKD.”

Fact: Conventional overall eGFR, creatinine, cystatin-C and ACR comparisons were not statistically significant. A secondary cystatin-C bootstrap analysis was positive but remains hypothesis-generating; the positive ACR result was in a 24-person subgroup over six months.

Myth 3: “The combination trial proves taurine works and NAC works.”

Fact: A fixed-combination study cannot separate the two ingredients or prove synergy.

Myth 4: “A lower creatinine means NAC repaired the kidneys.”

Fact: NAC can lower measured creatinine without changing cystatin C, especially after high-dose intravenous exposure. Trends need clinical and laboratory context.

Myth 5: “NAC protects everyone from contrast.”

Fact: ACT and PRESERVE were neutral. Current guidelines do not recommend routine NAC contrast prophylaxis.

Myth 6: “Dialysis removes taurine, so every dialysis patient needs it.”

Fact: Taurine levels vary by plasma and cell compartment, no deficiency threshold predicts benefit, and high-dose exposure accumulated despite dialysis.

Myth 7: “Natural means kidney-safe.”

Fact: The kidney clears many natural and synthetic compounds. Reduced clearance can turn an ordinary exposure into accumulation.

Myth 8: “More antioxidant means more protection.”

Fact: No CKD dose-response is established, and broad antioxidant trials have produced mixed benefits and harms.

Myth 9: “Energy drinks are an easy taurine treatment.”

Fact: They are multi-ingredient beverages, not CKD medicines. Caffeine, sugar, sodium or other additives can create separate problems.

Myth 10: “Taurine or NAC can replace an ACE inhibitor, ARB, SGLT2 inhibitor or finerenone.”

Fact: Neither has comparable kidney-outcome evidence. Any future role would be adjunctive, not substitutive.

Myth 11: “If doctors do not use them, the evidence is being suppressed.”

Fact: Both have been studied. The limitation is the absence of large, independent, replicated outcome trials and unresolved advanced-CKD safety—not a lack of scientific interest.

Myth 12: “If NAC is not proven for CKD, it is useless.”

Fact: Its emergency antidote and mucolytic roles are separate, established uses. One molecule can be proven for one indication and unproven for another.

Dr. Fowad’s evidence-based interpretation

Dr. Fowad’s evidence-based interpretation: “My position is neither supplement enthusiasm nor automatic dismissal. Taurine has credible renal biology, and NAC is a pharmacologically credible medicine. The new combination trial is encouraging enough to justify serious independent research—especially in persistent A2 albuminuria—but it is too small, too short and too dependent on subgroup biomarkers to change routine CKD practice.

“I would protect proven care first: establish the cause, measure eGFR and urine ACR, control blood pressure and diabetes, use outcome-proven kidney therapy where indicated, review nephrotoxins and monitor progression. I do not support routine taurine or NAC use for CKD on the current evidence. If either is considered in an exceptional, clinician-supervised context, it requires an exact product review, a defined reason, a monitoring plan and a stop plan. It should never be an energy-drink experiment, a substitute for proven therapy or a claim that the kidney has been ‘detoxified.’

“The most defensible conclusion today is not that taurine and NAC already protect every CKD patient. It is that the 2026 signal is interesting enough to deserve a larger, independent, intention-to-treat trial with sustained eGFR decline, kidney failure, cardiovascular events, safety and quality of life as prespecified outcomes.”

Questions to ask before considering any CKD supplement

1. What is the exact cause and stage of my CKD?
2. Is my urine ACR persistently elevated on repeat testing?
3. Have blood pressure, diabetes and established kidney-protective medicines been optimized?
4. Is there any human evidence for this exact product and my CKD population?
5. Is the evidence from an overall randomized comparison or only a small subgroup?
6. Does the product contain sodium, potassium, stimulants, herbs or other hidden ingredients?
7. Could my eGFR, dialysis schedule, transplant medicines or other drugs alter exposure or interactions?
8. What outcome would we monitor—ACR, creatinine, cystatin C, blood pressure, symptoms or adverse effects?
9. What change would make us stop it?
10. Who has verified the product’s manufacturer, regulatory status, storage and full label in Pakistan?

Frequently asked questions

1. Do taurine and NAC slow chronic kidney disease?

It is not proven. A small 2026 randomized combination trial found favourable biomarker directions and an ACR signal in a 24-person subgroup. Conventional overall eGFR, creatinine, cystatin-C and ACR comparisons were not statistically significant; a secondary cystatin-C bootstrap analysis was positive but remains hypothesis-generating. No definitive trial has shown less kidney failure or dialysis.

2. Which is better for CKD—taurine or NAC?

There is no reliable head-to-head CKD evidence. The newest trial used them together, so it cannot identify which ingredient contributed or whether both were necessary.

3. Can NAC lower creatinine?

NAC can slightly lower measured creatinine in some settings, particularly after high-dose intravenous use, without changing cystatin C. That may reflect laboratory interference rather than better filtration.

4. Can taurine reduce protein in urine?

Small combination studies have reported signals, but taurine-alone benefit has not been established. The main 2026 ACR signal came from a very small subgroup and needs independent replication.

5. Are taurine and NAC proven safe in CKD stage 3?

DELAY-CKD reported mild adverse events in five active-arm participants and none in placebo; all resolved, and swelling and tingling were judged likely or probably treatment-related. The small, highly selected six-month study did not reveal serious or persistent toxicity, but it cannot establish long-term safety or validate other formulations. Stage 3 CKD still requires review of medicines, blood pressure, sodium content, kidney trajectory and the exact product.

6. Are they safe in CKD stage 4 or 5?

There is insufficient efficacy and dosing evidence. Taurine accumulation and altered NAC exposure are particular concerns as kidney function falls. Do not self-start them.

7. Should dialysis patients take taurine because dialysis removes it?

Not routinely. Taurine handling in dialysis is complex, no validated deficiency threshold predicts benefit, and a small high-dose study found major accumulation and neurologic symptoms despite dialysis.

8. Does NAC prevent kidney injury from CT contrast or angiography?

Large trials did not show benefit, and current kidney/radiology guidance does not recommend routine NAC prophylaxis. Contrast decisions should be individualized by the treating and imaging teams.

9. Can taurine or NAC replace my ACE inhibitor, ARB or SGLT2 inhibitor?

No. They lack comparable hard-outcome evidence. Do not stop or reduce prescribed therapy without the clinician managing your CKD.

10. Is taurine in an energy drink the same as a studied product?

No. Energy drinks contain other ingredients and are not standardized CKD therapies. Their caffeine, sugar, sodium or stimulant content may be problematic.

11. Does “antioxidant” mean it prevents kidney scarring?

No. Antioxidant biology supports a hypothesis. Only long-term clinical trials can show whether an intervention meaningfully changes kidney scarring or outcomes.

12. Are the benefits proven in diabetic kidney disease?

No. Earlier diabetic-kidney studies were small and inconsistent. Diabetes control, blood pressure, ACE inhibitor/ARB therapy when indicated, SGLT2 inhibitors and selected finerenone have much stronger evidence.

13. Are these products approved for CKD in Pakistan?

This review does not identify or endorse any product as DRAP-authorized for slowing CKD. A product listing or supplement enlistment is not automatically a CKD indication. Exact current status must be verified product by product.

14. What research would change the answer?

A large, independent, adequately powered, intention-to-treat trial with prespecified ACR and eGFR outcomes, long follow-up, stage-specific safety and patient-important endpoints such as kidney failure, cardiovascular events and quality of life.

15. What should I do if I am already taking taurine or NAC?

If NAC was prescribed for a specific medical indication—or is being given for paracetamol poisoning—do not stop it without the treating team. For a self-purchased supplement, promptly show the exact product, dose and full label to the clinician or pharmacist managing your kidneys before continuing. Seek urgent care for severe breathlessness, facial or tongue swelling, wheeze, fainting, confusion, markedly reduced urine, persistent vomiting or rapidly worsening swelling.

16. Can pregnant or breastfeeding people, or children, use taurine or NAC for CKD?

CKD-specific benefit, dosing and safety have not been established in these groups. They should not be self-started.

17. Can kidney-transplant recipients use them?

No routine benefit has been established. Any product must first be reviewed by the transplant team for ingredients, quality and potential interactions; it must not replace transplant medicines or graft monitoring.

Explore additional evidence-led health reviews in Medical Insights.

References

1. Kidney Disease: Improving Global Outcomes (KDIGO). 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(Suppl 4S):S117–S314. Published March 2024. KDIGO 2024 CKD guideline (PDF)
2. Bhalla AK, Kumar S, Verma H, et al. The efficacy and safety of N-acetylcysteine and taurine in chronic kidney disease: a double-blind, multicenter, placebo-controlled trial (DELAY-CKD). Cureus. 2026;18(3):e105078. Published 11 March 2026. doi:10.7759/cureus.105078. DELAY-CKD PubMed record
3. Colombijn JMT, Hooft L, Jun M, et al. Antioxidants for adults with chronic kidney disease. Cochrane Database Syst Rev. 2023;11:CD008176. Published 2 November 2023. doi:10.1002/14651858.CD008176.pub3. Cochrane evidence review
4. Ye M, Lin W, Zheng J, Lin S. N-acetylcysteine for chronic kidney disease: a systematic review and meta-analysis. Am J Transl Res. 2021;13(4):2472–2485. Published 15 April 2021. PubMed record
5. Huang JW, Lahey B, Clarkin OJ, et al. A systematic review of the effect of N-acetylcysteine on serum creatinine and cystatin C measurements. Kidney Int Rep. 2021;6(2):396–403. Published online 3 December 2020. doi:10.1016/j.ekir.2020.11.018. PubMed record
6. Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine. N Engl J Med. 2018;378:603–614. Published online 12 November 2017. doi:10.1056/NEJMoa1710933. PRESERVE trial report
7. ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography. Circulation. 2011;124(11):1250–1259. Published online 22 August 2011. ACT trial PubMed record
8. Canadian Association of Radiologists. Guidance on contrast-associated acute kidney injury. Can J Kidney Health Dis. 2022;9. Published 2022. Full-text journal article
9. Suliman ME, Bárány P, Divino Filho JC, Lindholm B, Bergström J. Accumulation of taurine in patients with renal failure. Nephrol Dial Transplant. 2002;17(3):528–529. doi:10.1093/ndt/17.3.528. PubMed record
10. Jung BC, et al. Taurine levels in plasma and blood cells in patients undergoing routine maintenance hemodialysis. Am J Kidney Dis. 1991;18(1):74–79. doi:10.1016/S0272-6386(12)80293-9. PubMed record
11. Suliman ME, et al. Evidence of taurine depletion and accumulation of cysteinesulfinic acid in chronic dialysis patients. Kidney Int. 1996;50(5):1713–1717. doi:10.1038/ki.1996.490. PubMed record
12. Viswanathan V, et al. Effect of taurine and acetylcysteine in attenuating microalbuminuria in type 2 diabetes. Indian J Nephrol. 2008;18(2):85. doi:10.4103/0971-4065.42349. Full-text journal article
13. Sengupta P, Biswas S, Roy T. Comparative study of low-protein diet supplementation with taurine and N-acetylcysteine, and N-acetylcysteine plus pyridoxamine, in non-diabetic kidney disease. J Assoc Physicians India. 2022;70(5):11–12. PubMed record
14. Renke M, Tylicki L, Rutkowski P, et al. The effect of N-acetylcysteine on proteinuria and markers of tubular injury in non-diabetic patients with chronic kidney disease. Kidney Blood Press Res. 2008;31(6):404–410. doi:10.1159/000185828. PubMed record
15. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients undergoing hemodialysis. Circulation. 2003;107(7):992–995. Published 25 February 2003. PubMed record
16. Ahmadi F, Abbaszadeh M, Razeghi E, et al. Effectiveness of N-acetylcysteine for preserving residual renal function in patients undergoing maintenance hemodialysis: multicenter randomized clinical trial. Clin Exp Nephrol. 2017;21(2):342–349. doi:10.1007/s10157-016-1277-5. PubMed record
17. Nolin TD, et al. Pharmacokinetics and pharmacodynamics of N-acetylcysteine in end-stage renal disease. Clin J Am Soc Nephrol. 2010;5(9):1588–1594. doi:10.2215/CJN.00210110. Full-text journal article
18. Heneberg P, Heneberg Šimčíková D. Untangling amino acid metabolism in renal diseases. Clin Kidney J. Published 4 December 2025; 2026 issue. Full journal article
19. U.S. Food and Drug Administration. Agency response letter, GRAS Notice No. 586: taurine. 9 December 2015. FDA source
20. Drug Regulatory Authority of Pakistan. Alternative medicines and health products: product categories. Accessed 20 August 2026. DRAP product-category guidance
21. U.S. National Library of Medicine DailyMed. Acetylcysteine injection prescribing information. Revised December 2025; accessed 20 August 2026. Official acetylcysteine prescribing information
22. Premanath M, Mahesh M, Babu MS, Bhanukumar M, Devananda D. Int J Health Allied Sci. 2019;8:236–241. doi:10.4103/ijhas.IJHAS_27_19. Journal article DOI
23. Singh AK, Agarwal P, Kaushik S. Asian J Pharm Clin Res. 2017;10(2):230–232. doi:10.22159/ajpcr.2017.v10i2.15369. Journal article DOI

Educational disclaimer

This article is for general education and evidence review. It does not diagnose CKD, recommend a supplement, provide a dose, establish that any product is registered or available in Pakistan, or replace care from a physician, nephrologist, pharmacist or dietitian. CKD changes the handling and safety of medicines and supplements. Do not start, stop or change taurine, NAC, an energy drink, a prescribed medicine or a contrast plan without individual clinical review. Seek urgent care for severe breathlessness, chest pain, fainting, rapidly worsening swelling, markedly reduced urine, confusion, severe vomiting, a serious allergic reaction or another acute deterioration.